IECM
SBBP

Intrinsic Edge Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Intrinsic Edge Capital Management’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200,000
Closed -$970K – 189
2018
Q3 		$970K Hold
200,000
– – 0.16% 118
2018
Q2 		$1.2M Buy
+200,000
New +$1.46M 0.14% 119

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Intrinsic Edge Capital Management's SBBP Position: Q4 2018 in Review

Intrinsic Edge Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2018, closing a stake of 200,000 shares — an estimated $970K sold.

Intrinsic Edge Capital Management first reported a position in SBBP in Q2 2018 and held it in 2 quarters. The position peaked at $1.2M in Q2 2018. 42 funds tracked by Wall St. Rank hold SBBP as of Q4 2018.

  • Intrinsic Edge Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q4 2018 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 200,000 Strongbridge Biopharma plc. shares in Q4 2018, an estimated $970K.
  • Intrinsic Edge Capital Management first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 2 quarters.
  • Intrinsic Edge Capital Management's Strongbridge Biopharma plc. position peaked at $1.2M in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2018.

Based on Intrinsic Edge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.